Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression

Human epidermal growth factor receptor‐2 (HER‐2) overexpression in breast tumor tissues is associated with a poor prognosis but may benefit from treatment with trastuzumab. The extracellular domain (ECD) of HER‐2 can be measured in serum and which has been a new inspection item in clinical laborator...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Hui, Zhong, Ailing, Xie, Suhong, Wang, Yanchun, Sun, Jiajun, Zhang, Jie, Tong, Ying, Chen, Miaomiao, Zhang, Guihong, Ma, Qian, Kai, Jinyan, Guo, Lin, Lu, Renquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382724/
https://www.ncbi.nlm.nih.gov/pubmed/30661303
http://dx.doi.org/10.1002/cam4.1859

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6382724/
https://www.ncbi.nlm.nih.gov/pubmed/30661303
http://dx.doi.org/10.1002/cam4.1859

Ejemplares similares